AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Validation and Cross-Ancestry Evaluation of Hypertrophic Cardiomyopathy Polygenic Score in a Diverse Population-Based Cohort

By Pancholy M, Le Q, Bhandari A et al.

Background: Polygenic scores (PGS) aggregate common genetic variants to estimate disease risk, but their performance in diverse populations remains understudied. We evaluated the recently developed hypertrophic cardiomyopathy (HCM) PGS, PGS004911, across multiple ancestries in the All of Us Research Program. Methods: We analyzed 409,423 participants with short-read whole-genome sequencing data. Two complementary case definitions were prespecified: Phenotype A (broad, ≥2 HCM diagnostic codes; n=813) and Phenotype B (drug-treated subset with disopyramide or verapamil/diltiazem plus metoprolol, atrial-fibrillation-excluded; n=157). Ancestry-stratified and admixture-aware pooled logistic regression evaluated odds ratios, discrimination via the area under the receiver operating curve (AUROC), and 10-fold cross-validated calibration (intercept α, slope β, Brier). Phenome-wide association (PheWAS) testing and rare sarcomere-variant penetrance analyses were also performed. Results: Under Phenotype A, the HCM PGS was associated with HCM in European (EUR; 562 cases, OR 1.73 per SD, 95% CI 1.59-1.87), African (AFR; 164, OR 1.32, 1.14-1.54), and Admixed-American (AMR; 69, OR 1.39, 1.11-1.75; all P≤0.005) ancestries; effect sizes were larger under Phenotype B (EUR OR 1.94; AFR OR 1.45). The top 1% of EUR participants had 4.55-fold higher HCM odds versus the median. Calibration was strong in EUR and pooled (β=0.95-0.96) but attenuated in AFR (0.72) and AMR (0.74). Among carriers of pathogenic sarcomere variants, above-median PGS nearly doubled penetrance (8.85% vs 4.68%, P=0.013). PheWAS replicated the inverse HCM-dilated cardiomyopathy relationship (OR 0.76, P<0.001). Conclusions: The HCM PGS replicates across diverse ancestries with attenuated discrimination and calibration outside European populations. Common polygenic variation multiplicatively modifies sarcomere-variant penetrance. Ancestry-specific recalibration is required before clinical deployment. Figure 1: Association of PGS-predicted HCM with phenotypic HCM. Figure 2: 10-fold cross-validated cross-validation plots under phenotype A for each ancestry. Figure 3: PheWAS of HCM PGS against 17 cardiac and cardiometabolic conditions.

doi.org/10.1161/circ.154.suppl_1.18585Biomarkers

AgingResearch.News